Leading German pharmaceutical manufacturer and homecare provider
APOSAN (“the Company”) was founded in 1991 with the purpose to service homecare patients through the compounding of individualised infusible and injectable medication. Since then, the Company has evolved to an integrated full-range pharmaceutical homecare supplier with its own manufacturing capacities and dedicated key account management, as well as homecare nurses team to generate and support its growing nationwide patient base.
The APOSAN group of companies was organised in three main business segments: pharmaceutical homecare, providing services to patients that require long-term infusion to diseases; classical homecare, providing standard enteral nutrition solutions as well as selected standard medical devices; and ophthalmic injectables. APOSAN is headquartered in Cologne, Germany and served over 10,000 patients per year at the time of exit.
IK acquired a majority stake in APOSAN in October 2016 from the founder. In September 2020, APOSAN was sold to Santé Cie, a leading French home medical assistance provider and a portfolio company of Ardian.
Our Value Creation Strategy
During our ownership, we worked alongside the management team to:
- Support organic growth in existing medications and homecare antibiotic treatments;
- Grow intravenous product portfolio and further expand into adjacent areas in homecare;
- Expand production capacity through investment into manufacturing facilities; and
- Develop the sales and marketing organisation, with a focus on improving incentivisation.
Quote from the Client
“APOSAN has achieved strong growth over the past years and has made substantial investments in the Company. We would like to take this opportunity to thank IK Investment Partners for all their support, which enabled APOSAN to grow and expand its market position and offering. We now look forward to working with Santé Cie to further build on this success.”
Rainer Schmitz, Managing Director, APOSAN